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Summary 
The results of a previous 4-rot study in azaserine-treated rats and BOP-treated hamsters indicated that 
orchiectomy inhibited pancreatic growth and development of putative preneoplastic lesions in the exo- 
crine pancreas of rats but not hamsters. This 12-rot study was carried out to investigate the effects of 
orchiectomy, alone and in combination with testosterone, and of treatment with cyproterone acetate on 
pancreatic carcinogenesis in azaserine-treated rats and BOP-treated hamsters. Treatment s arted 4 mo after 
injection of the carcinogen~ In orchiectomized rats, pancreatic wt was lower than in controls, whereas 
pancreatic wt of orchiectomized rats treated with testosterone was similar to that of controls. Both 
orchiectomy and cyproterone acetate caused adecrease in body wt gain and had an inhibitory effect on 
pancreatic carcinogenesis. Testosterone treatment did not influence the inhibitory effects of orchiectomy 
on body wt gain and on pancreatic carcinogenesis. In hamsters, neither orchiectomy, alone or in combina- 
tion with testosterone, nor cyproterone acetate (CA) affected pancreatic growth or pancreatic carcinogenesis. 
This study indicates that estosterone plays a minor ole in the development of pancreatic tumors induced 
in rats by azaserine but not in that of pancreatic tumors induced in hamsters by BOP. 
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Introduction 
In most countries, the age-adjusted incidence of 
pancreatic ancer is higher in men than in women 
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(1,2). Apart from life-style factors, hormonal factors 
have been suggested to be responsible for this sex 
difference. A higher number of atypical acinar cell 
nodules (AACN) and a higher incidence of pancre- 
atic neoplasms have been found in male than in 
female rats treated with azaserine (3). Using the AT- 
Pase staining, Bax et al. found that acidophilic loci in 
male rats were consistently arger (1.75 times) than 
in females and concluded that the sex-related differ- 
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ence in the numbers of acidophilic AACN induced in 
rat pancreas by azaserine may be ascribed to the dif- 
ficulty in detecting small acidophilic foci in hema- 
toxylin and eosin (H&E)-stained sections (4). In 
rats, the inhibitory effect of castration on growth of 
azaserine-induced AACN has been ascribed to decreased 
serum testosterone levels (5-7). The inhibitory effect 
of castration, however, was not influenced by treat- 
ment with testosterone. In a previous 4-too study with 
azaserine-treated rats, we also found an inhibitory 
effect of orchiectomy on the development of AACN, 
which was accompanied by a significant decrease in 
absolute but not relative pancreatic wt. From the 
results of that study, we concluded that, apart from 
testosterone, nutritional status and pancreatic growth 
may play a highly significant role in the development 
of putative pancreatic preneoptastic lesions (8). 
No consistent variations have been found in inci- 
dence of pancreatic (pre)neoplastic lesions in male 
and female hamsters induced by sc injections with 
nitrosamine derivatives. Pour et al. did not find a 
difference between male and female hamsters inthe 
incidence of pancreatic tumors after injection with 
N-nitrosobis (2-oxopropyl)amine (BOP) (9,10). 
Kokkinakis, on the contrary, found that tumor inci- 
dence, multiplicity, and Size were generally larger in 
female than in male hamsters after administration f 
N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine 
(HPOP) (11). Pancreatic (H2T) ceils transplanted in 
hamster cheek pouches developed faster into ductat 
adenocarcinomas in intact females and castrated males 
than in ovariectomized females and intact males, 
respectively, pointing to an inhibitory effect of tes- 
tosterone or an enhancing effect of estrogen (12). 
SchaUy and co-workers, however, found that the 
development of pancreatic tumors induced in male 
hamsters by BOP was inhibited by medical or surgi- 
cal castration (13-18). Furthermore, in a previously 
conducted 4-mo study, we did not find any effect of 
castration or Luteinizing Hormone Releasing Hor- 
mone (LHRH) treatment on the development of early 
(pre)neoplastic lesions induced in hamster pancreas 
by BOP (8). This experiment was performed toevalu- 
ate the effects of castration, either alone or in combi- 
nation with testosterone h-eatment, and of treatment 
with the antiandrogen cyproterone acetate (CA) on 
pancreatic carcinogenesis in hamsters and rats during 
a long-term treatment period of 8 mo started 4 mo 
after tumor induction. 
Materials and Methods 
Animals and Tumor Induction 
Two hundred male weanling SPF albino Wistar Bor 
rats (WISW, Cpb) were obtained from F. Winkelmann 
(FRG) and injected ip four times with 30 mg 
azaserine/kg body wt at 19, 26, 33, and 103 d of 
age. One hundred and forty male Syrian golden 
hamsters (Charles River Wiga, Sulzfeld, FRG) were 
each injected sc, once weekly, with 20 mg BOP/kg 
body wt at 6, 7, and 8 wk of age according to an 
injection protocol described previously (19). BOP 
(Ash Stevens, Inc., 5861 John C. Lodge Freeway, 
Detroit, MI 48202) and azaserine (Calbiochem- 
Behring Corp., LaJolla, CA) were dissolved freshly 
in 0.9% NaC1 solution. The animals were allocated 
by a computerized randomization procedure to four 
different groups, each of which consisted of either 50 
rats or 35 hamsters. The rats were housed in stain- 
less-steel cages, fitted with wiremesh floors and fronts, 
and the hamsters inmacrolon cages on softwood bed- 
ding. The animals were kept under standard labora- 
tory conditions, five animals per cage, and fed a high 
fat/high protein diet during the first 4 mo of the study 
in order to enhance the development of ductular lesions 
in the exocrine pancreas. 
Treatment 
In order to mimic the human situation, treatment 
started when early (pre)neoplastic lesions had already 
developed in the pancreas, i.e. 4 mo after the last injec- 
tion with carcinogen. The animals received one of the 
following treatments: group A, saline (controls); group 
B, surgical castration; group C, surgical castration plus 
testosterone; and group D, CA. Testosterone was 
administered astestosterone proprionate by silastic 
implants as described previously (20). Rats received 
two, 3-cm implants per animal, and hamsters, inview 
of lower body wt, received one implant per animal 
once at start of treatment. Cyproterone acetate was 
used as Androcur tablets (50 rag) dispersed in tap 
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water. The animals were given CA by gavage daily at 
a dose of 50 mg/kg, as described previously (21). 
During treatment, the animals were fed the TNO 
Institute's basal diet, which is Iow in fat (5%) and 
compounded from natural feed ingredients. Body wt 
were recorded weekty during the first 3 mo and once 
a month during the rest of the experiment. The gen- 
eral condition and behavior of the animals were 
checked aily. 
Autopsy and Histological Analysis 
In rats, an interim kill was performed on 20 ani- 
mals of each group after 4 mo of treatment. Terminal 
autopsy on rats and hamsters was performed after 8 
mo of treatment on days 371 (rats), and 363 and 364 
(hamsters) after the last injection with carcinogen. The 
animals were anesthetized by ether, exsanguinated by 
cannulating the abdominal orta, autopsied, and then 
examined for gross pathological changes. From each 
animal, the pancreas, liver, testes (if present), adrenals, 
and pituitary were excised and weighed. These 
organs were fixed in 10% buffered formalin. The 
pancreata were completely processed for microscopy 
by conventional methods, step-sectioned at 5 ~m 
(about 5per pancreas), stained with H&E, and exam- 
ined by light microscopy. About 200 mm 2 of pancre- 
atic tissue of each rat were microscopically screened 
for the number and size of azaserine-induced AACN 
using a grid inside the ocular as described before (22). 
Only acidophilic AACN with transection areas greater 
than 0.5 mm 2 have been counted and classified. 
AACN, acinar cell adenomas (AACN with a 
transection area larger than 3 mm2), and (localized) 
carcinomas were identified and classified according 
to the criteria of Longnecker t aL (3,23). 
In the hamster pancreas, major attention was paid 
to tubular ductal complexes howing dysplasia or 
anaplastic changes, or desmoplasia, inflammation, 
with or without apoptosis, uggestive ofprogression 
to malignancy. Tubular ductal complexes exhibiting 
one or more of the characteristics were classified as 
"borderline l sions" (24). The ductular carcinomas 
induced by BOP were identified and classified 
according to Pour and Wilson (25). 
Body and organ wt data were statistically evalu- 
ated with one-way analysis of variance (ANOVA) 
using initial body wt as covariable. The number of 
borderline and other (pre)neoplasfic lesions were sta- 
tistically evaluated with a generalized linear model 
(26). With such a model, the effects of type of treat- 
rnent (control, surgical castration, surgical castration 
plus testosteror~, or CA) were assessed. For rats, the 
influence of time of sacrifice (interim kill, terminal 
autopsy) and possible interaction between type of 
treatment and time of sacrifice were assessed as well. 
A Poisson error distribution was used for evaluation of 
the lesions. 
Evaluation of the prevalence (incidence) of tu- 
mors (terminal autopsy animals only) was done with 
a generalized linear model. The difference with the 
model used for lesions was the error distribution. 
With respect to prevalence, the binomial distribu- 
tion was appropriate. 
Endocrine Investigations 
Blood sampling for hormone stimations was per- 
formed at the start of the treatment period (n = 19- 
20), after 4 mo (n = 10) and after 8 mo (n = 10) of 
treatment a the end of the experiment by exsang- 
uination. In groups of five animals, blood sampling 
was also performed after 2 and 6 mo by orbita 
punctions. In Table 1, only the data obtained at 0, 4, 
and 8 mo after treatment have been included. EGF- 
and IGF-l-like activities were measured inacid-etha- 
nol extracted EDTA-plasmas by radioreceptor assays 
using human placental membrane preparations a  
receptor source. All procedures were exactly as 
described before for determination f EGF- and IGF- 
l-like activities in human breast tumor cytosols (27). 
Growth hormone (GH) levels were determined by 
radioimmunoassay (RIA) (28). Testerone l vels were 
estimated as described by Verjans et al. (29). The treat- 
meat effects on plasma hormone and growth factor 
levels were determined by ANOVA on the pooled 
data of all treatment groups and controls at the end of 
treatment. Small p values from these analyses, per- 
formed for each growth factor or hormone in rats 
and hamsters, are an indication of a difference in 
effect, either a decrease or increase of plasma 
concentrations. In addition, to prevent the influ- 
ence of outflyers, the Wilcoxon test has also been 
applied where useful. 
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Table 1 
Treatment Effects on Plasma Growth Factor and Hormone Levels 
Postinitiation 
treatment group 
GH (ng/mL} 
0 Mo 4 Mo 8 Mo 0 Mo 
-Testosterone (nmol/L) 
4 Mo 8 Mo 
Rats 
Controls 11.7 _+ 4.1 b 
Castration 
Castration + T ~ 
CPA 
p value ~ 
Hamsters 
Controls 5.5 + 1.6 
Castration 
Castration +T a 
CPA 
p value" 
Postinitiation 
treatment group 0 Mo 
2.4 _+ 0.8 16.9 + 6.2 (12) c 11.6 + 3.2 
5.7 + 1.8 3.0 + 0.7 (10) c - -  
11.3-+3.2 20.8_+9.1 (10) c - -  
24.5 _+ 14.4 14.8 _+ 6.6 (12) c - -  
p = 0.29 
EGF (ng/mL) 
4 Mo 
2.7 _+ 0.5 4.6 + 0.6 (10) c 
0.1 + 0.0 0.1 _+ 0.0 (10) c 
16.9 _+ 1.2 10.2 + 1.2 (10) c 
5.3_+ 1.3 11.6_+3.1 (12) c 
p = 0.0003 
2,8+0.7((12)  c 15.3+4.2 6 .3+0.8 17.0+5.1 (10) c 
4.3 + 0.6 (113) c - -  0.1 _+ 0.0 0.1 +_ 0.0 (10) c 
2.0 + 0.5 (9) c - -  3.8 _+ 1.3 2.2 _+ 0.5 (10) c 
3.3 -+ 0.5 (12) c - -  10.8 + 1.5 13.0 + 2.2 (7) c 
p = 0.09 p = 0.0000 
IGF (ng/mL) 
8/rio 0 Mo 4 Mo 8 Mo 
Rats 
Controls 29.0 _+ 4.5 
Castration 
Castration + T d 
CPA 
p value a
Hamsters 
Controls 22.2 + 1.8 
Castration 
Castration +T ~ 
CPA 
p value a
53.4 + 6.3 
68.2 -+ 8.7 
46.7 -+ 10.1 
15.2 + 6.5 
47.6 + 31.2 (12) c 131_+9 200_+11 101+_14(12) c 
43.4 +_ 8.8 (10) c - -  191 -+ 16 94 -+11 (10) c 
31.0 -+ 5.1 (9) c - -  161 _+19 107 + 14 (10) c 
45.2 -+ 28.7 (12) c - -  145 + 11 127 + 16 (12) c 
p = 0.97 p = 0.35 
62.8 + 4.5 (12) c 255 • 14 - -  144 _+ 7 (12) c 
60.8 _+ 5.5 (10) c - -  - -  244 + 19 (10) c 
60.0 + 5.5 (10) c - -  - -  194 + 15 (10) c 
76.5 _+ 5.6 (13) c - -  - -  206 + 18 (13) c 
p = 0.09 p = 0.0005 
'~P value associated with test of difference between the five groups after 8 mo of treatment, bAll values are means +SEM. CNumber of 
animals used at 8 mo between brackets; at start of treatment 19-20 animals, and after 4 mo 10 animals were used for assays. 
d r= testosterone. 
Results 
Body Weights 
In rats but not hamsters, orchiectomy inhibited body 
growth by 19% (p < 0.01) (Figs. 1,2; Tables 2,3). Body 
wt o f  orchiectomized rats treated with testosterone 
was also significantly lower  (15%) than that o f  con- 
trols. Rats treated with CA also showed a lower body 
wt (p < 0.01) than controls, whereas body wt of  ham- 
sters treated with CA had increased by 10% (p < 0.05) 
compared to controls. 
Organ Weights 
In rats, absolute but not relative pancreas wt had 
decreased (p < 0.01) by orchiectomy and by treat- 
ment  with CA (p < 0.05), when compared with con- 
trois (Table 2). Suppletion with testosterone r stored 
greatly the loss o f  absolute pancreas wt caused by 
orchiectomy, resulting in the absence o f  a significant 
difference with the control group. 
In  o rch iec tomized  rats, abso lute  and re lat ive 
pituitary wt increased (p < 0.01). Supplet ion with tes- 
tosterone prevented the absolute increase but not the 
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Fig. 1. Mean body wt in rats. O = control; [] = 
castration; ~ = castration +testosterone; and @ = CA. 
relative increase in pituitary wt. Adrenal wt was not 
significantly affected by any of the treatment modalities. 
In rats, absolute liver wt was lower (p < 0.01) in all 
treated groups, whereas relative liver wt was only 
lower in orchiectomized rats not treated with testos- 
terone (p < 0.01). In hamsters, apart from an increase 
of pituitary wt by castration, none of the treatments 
significantly influenced absolute or relative organ wt 
(Table 3). 
Plasma Growth Factor 
and Hormone Levels 
In rats, significant differences among groups were 
observed at the end of the experiment with respect to 
EGF- and IGF-l-like activity and plasma GH levels 
(Table 1). Plasma IGF-1 levels increased until 4 mo 
of treatment and subsequently decreased toadult val- 
ues when the growth curves were (nearly) flattened. 
Plasma GH levels tended to decrease after surgical 
castration and to increase in case of testosterone sub- 
stitution, but the differences were not significant 
compared to controls (by ANOVA and Wilcoxon- 
test analyses). During the treatment period, plasma- 
testosterone concentrations were lower than before 
in the control group, maybe as a consequence of late 
damage of testicular function by carcinogens. As 
expected, surgical castration caused very low plasma 
testosterone l vels. Substitution with testosterone 
implants caused significant plasma testosterone con- 
centrations comparable with those present in the con- 
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Fig. 2. Mean body wt in hamsters. O = Control; [] = 
castration; ~ = castration +testerone; and @ = CA. 
trol group before treatment. Cyproterone acetate did 
not decrease plasma testosterone, as could be expected. 
In hamsters, no differences were found among 
groups with respect to EGF-like activity, whereas IGF- 
1 levels were higher in the treatment groups compared 
with those of controls (all p < 0.01, Wilcoxon test). 
Although plasma GH tended to be higher in castrated 
animals, overall there were no clear differences among 
groups. As expected, after castration, plasma testos- 
terone levels were very low. Testosterone substi- 
tution caused significant plasma testosterone concen- 
trations, but lower than in rats possibly as a conse- 
quence of the lower dose used. 
Microscopy 
In rats, multiplicity of lesions increased signifi- 
candy in time (Table 4). After 8 mo of treatment, he 
number of AACN with transection areas larger than 
0.5 mm 2 was lower (p < 0.01) in each of the treatment 
groups in comparison with controls. The number of 
adenomas was similar in all groups, controls included~ 
The total number (multiplicity) but not the incidence 
(Table 6) of carcinomas was lower (p < 0.05) in all 
treatment groups after 8 mo of treatment (Table 4). 
In hamsters, none of the treatments had a signifi- 
cant effect on either the number of borderline lesions, 
the multiplicity orthe incidence of carcinomas (Tables 
5,6). Surgical castration decreased the number and the 
incidence of total carcinomas with about 50%, but this 
difference did not appear to be statistically significant. 
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Table 5 
Treatment Effects on Number of (Pre)neoplastic Lesions 
in Exocrine Pancreas of BOP-Treated Hamsters a'b 
Number of lesions 
Advanced Ductular Castration + Cyproterone 
Lesions Observed Control Castration testosterone acetate 
Effective number 
of animals 26 26 26 28 
Borderline lesion 227 214 204 221 
Carcinoma in situ 5 0 0 2 
Microcarcinoma 5 1 3 0 
Carcinoma 5 6 8 11 
Total carcinoma 15 7 11 13 
avalues are totals per group, bstatistics: log-linear model with a Poisson error distribution. There were no 
significant differences between the treatments. 
Table 6 
Treatment Effects on Incidence of Carcinomas 
in Exocr ine Pancreas of  Azaserine-Treated Rats and BOP-Treated Hamsters 
Neoplastic lesion observed 
Number of lesions 
Castration + Cyproterone 
Control Castration testosterone acetate 
Incidence of pancreatic arcinomas in rats a 
Effective number of animals 
Number of animals bearing a lesion 
Incidence of pancreatic arcinomas in hamsters b 
Effective number of animals 
Number of animals beating a lesion 
29 26 24 29 
11 6 7 13 
26 26 26 28 
14 7 10 10 
astatistics: generalized linear model with a binomial error distribution, bStatistics: generalized linear model with a binomial error 
distribution. There were no significant differences between the treatments. 
Discussion 
The results of the present 12-mo study indicate that 
orchiectomy and treatment with CA cause a decrease 
in body wt gain and absolute pancreatic wt in rats but 
not hamsters and inhibition of pancreatic carcinogene- 
sis in azaserine-treated rats but not BOP-treated ham- 
sters. Moreover, treatment of orchiecto-mized rats 
with testosterone did not affect the inhibitory effect 
of surgical castration on body wt gain in spite of the 
presence of normal plasma testosterone l vels, 
whereas pancreas wt of testosterone-treated castrated 
rats had increased in comparison to orchiectomized 
rats not treated with testosterone. 
The conclusion that testosterone has an enhancing 
effect on pancreatic arcinogenesis n azaserine- 
treated rats has been based on the observation that 
orchiectomy and estradiol treatment inhibited the de- 
velopment of AACN (6,7). In a previously performed 
4-mo study with azaserine-treated rats (8), we also 
found that orchiectomy reduced the yield of AACN 
significantly, but this effect was accompanied by a 
significant decrease in growth of absolute pancreatic 
wL After correction for pancreas wt, the number of 
AACN in the orchiectomized rats was almost similar 
to that in intact controls (8). 
Based on these findings, we concluded that a sub- 
stantial decrease in body growth rate as observed in 
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surgically castrated rats has to be considered a con- 
founding factor in such experiments, which, if not 
taken into account, may have led to an overestima- 
tion of the direct, enhancing effect of testosterone on
pancreatic carcinogenesis. 
The results of this study support this conclusion, 
since it appears that castrated rats treated with testos- 
terone develop even less AACN in comparison with 
castrated rats not treated with testosterone (Table 4). 
Treatment of orchiectomized rats with testosterone 
did not result in a tumor yield similar to that of intact 
controls, notwithstanding the fact that pancreatic wt 
in the testosterone-treated group was almost similar 
to that of controls. This observation i dicates that 
changes in body wt during different reatment 
modalities are at least as important as changes in 
plasma-testosterone concentrations. On the other 
hand, the level of plasma testosterone concentrations 
might be of importance, i.e., high and castration lev- 
els, inhibitory and intermediate l vels, stimulatory. 
In agreement with this hypothesis are the findings of 
Greenway and colleagues (30), showing low but not 
castration levels of testosterone in patients with car- 
cinoma of the pancreas. Furthermore, relative loss of 
body wt might decrease (intratumoral) aromatase 
activity, resulting in a decreased conversion of andro- 
gens to estrogens. 
The findings in hamsters are in agreement with 
those in our previous 4-too study (8). In BOP-treated 
hamsters, orchiectomy did not influence body wt gain, 
and only slightly but not significantly inhibited pan- 
creatic arcinogenesis. The present findings upport 
partly those of Zalatnai and Schally (13-18) who 
found a significant decrease in tumor wt and tumor 
volume but no effect on the incidence of ductular 
adenocarcinomas in chemically (LHRH-treated) cas- 
trated (BOP-treated) hamsters. 
Based on the aforementioned findings, it might be 
possible that early putative preneoplasfic a inar and 
ductular lesions, which develop in the pancreas of rats 
and hamsters after treatment with azaserine and BOP, 
respectively, do not contain steroid receptors and, 
hence, cannot be modulated by testosterone. It may 
be concluded, therefore, that manipulation fpancre- 
atic carcinogenesis by steroid hormones i only red 
evant for the treatment ofexisting carcinomas. 
Based on the findings described in this article, it 
may be concluded that he observed inhibitory effects 
of orchiectomy and cyproterone acetate on pancre- 
atic carcinogenesis in azaserine-treated rats may, at 
least partly, be ascribed to a significant decrease in 
body growth~ However, the mechanism of action of 
relative delay in body growth on pancreatic carcino- 
genesis is still unclear. Importantly, we did not 
observe a significant decrease in GH and growth 
factor secretion, or in our previous tudy in gastrin 
secretion (8). Therefore, studies on the effect of rela- 
tive wt loss on other factors potentially involved in 
pancreatic carcinogenesis are needed. 
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